Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek naar de werkzaamheid van JNJ-89495120 bij de behandeling van depressieve stoornissen (Moonlight-1)

24 september 2026 bijgewerkt door: Janssen Research & Development, LLC

Een gerandomiseerde, dubbelblinde, multicenter, placebogecontroleerde, proof-of-concept-studie om de werkzaamheid, veiligheid en verdraagbaarheid van JNJ-89495120 als monotherapie bij volwassen deelnemers met depressieve stoornis (MDD) te evalueren

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Studie Overzicht

Toestand

Voltooid

Studietype

Ingrijpend

Inschrijving (Werkelijk)

105

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alabama
      • Huntsville, Alabama, Verenigde Staten, 35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler, Arizona, Verenigde Staten, 85224
        • Chandler Clinical Trials
      • Phoenix, Arizona, Verenigde Staten, 85012
        • IMA Clinical Research PC Phoenix
      • Tucson, Arizona, Verenigde Staten, 85724
        • University of Arizona
      • Tucson, Arizona, Verenigde Staten, 85704
        • Noble Clinical Research
    • California
      • Bellflower, California, Verenigde Staten, 90706
        • CI Trials
      • Encino, California, Verenigde Staten, 91316
        • Wake Research PRI Encino
      • Garden Grove, California, Verenigde Staten, 92844
        • National Institute Of Clinical Research
      • Newport Beach, California, Verenigde Staten, 92660
        • WR-Newport Beach
      • Orange, California, Verenigde Staten, 92866
        • ATP Clinical Research
      • Redlands, California, Verenigde Staten, 92374
        • Anderson Clinical Research
      • San Diego, California, Verenigde Staten, 92103
        • Artemis Institute for Clinical Research
      • San Jose, California, Verenigde Staten, 95124
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, Verenigde Staten, 92705
        • Syrentis Clinical Research
      • Temecula, California, Verenigde Staten, 92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek, California, Verenigde Staten, 94596
        • Sunwise Clinical Research
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers, Florida, Verenigde Staten, 33912
        • Gulfcoast Medical Research Center
      • Hollywood, Florida, Verenigde Staten, 33021
        • The Medici Medical Research
      • Homestead, Florida, Verenigde Staten, 33030
        • Advanced Research Institute of Miami
      • Maitland, Florida, Verenigde Staten, 32751
        • K2 Medical Research
      • Miami, Florida, Verenigde Staten, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, Verenigde Staten, 33135
        • Wellness Research Center
      • Pembroke Pines, Florida, Verenigde Staten, 33024
        • Best Choice Medical and Research Service
      • Tampa, Florida, Verenigde Staten, 33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach, Florida, Verenigde Staten, 33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Verenigde Staten, 30030
        • iResearch Atlanta LLC
      • Snellville, Georgia, Verenigde Staten, 30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70115
        • DelRicht Research
    • Maryland
      • Gaithersburg, Maryland, Verenigde Staten, 20877
        • CBH Health
    • Massachusetts
      • Worcester, Massachusetts, Verenigde Staten, 01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn, New York, Verenigde Staten, 11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • University of Cincinnati
      • Cincinnati, Ohio, Verenigde Staten, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, Verenigde Staten, 43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston, South Carolina, Verenigde Staten, 29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney, Texas, Verenigde Staten, 75071
        • Revival Research Institute LLC
    • Utah
      • Clinton, Utah, Verenigde Staten, 84015
        • Alpine Research Organization
    • Washington
      • Everett, Washington, Verenigde Staten, 98201
        • Core Clinical Research

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 64 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

Experimenteel: Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

Placebo-vergelijker: Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Tijdsspanne: Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in MADRS Total Score to Day 2
Tijdsspanne: Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Tijdsspanne: Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Tijdsspanne: Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Tijdsspanne: Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
Tijdsspanne: Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
Tijdsspanne: Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Tijdsspanne: Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
Tijdsspanne: Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Tijdsspanne: Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Tijdsspanne: Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Tijdsspanne: From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Tijdsspanne: From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
Tijdsspanne: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

26 december 2024

Primaire voltooiing (Werkelijk)

25 juni 2026

Studie voltooiing (Werkelijk)

10 augustus 2026

Studieregistratiedata

Eerst ingediend

15 januari 2025

Eerst ingediend dat voldeed aan de QC-criteria

15 januari 2025

Eerst geplaatst (Werkelijk)

20 januari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 89495120MDD2001
  • 89495120MDD2001 (Andere identificatie: Janssen Research & Development, LLC)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren